Denali Therapeutics (DNLI) Shares Issued (2017 - 2018)

Denali Therapeutics' (DNLI) quarterly Shares Issued came in at $1.5 million in Q1 2018, down 78.05% on a QoQ basis from $6.7 million in Q4 2017.

Denali Therapeutics (DNLI) Shares Issued (2017 - 2018) Analysis & Trends

Denali Therapeutics (DNLI) has 2 years of Shares Issued data on file, last reported at $1.5 million in Q1 2018.

On a quarterly basis, Shares Issued changed N/A year-over-year to $1.5 million in Q1 2018; TTM through Mar 2018 was $1.5 million, a N/A change from a year earlier, with the FY2017 full-year figure at $6.7 million, changed N/A from the prior year.
Shares Issued for Q1 2018 stood at $1.5 million, down from $6.7 million in the prior quarter.
Over the last five years, Shares Issued for DNLI reached as high as $6.7 million in Q4 2017 and fell as low as $1.5 million in Q1 2018.

#	Company	Market Cap	Enterprise Value	Gross Profit (Qtr)	Shares Issued (Qtr)
1	Oculis Holding AG	67,072.09 Bn	67,072.09 Bn	-	-
2	Nanobiotix	1,894.61 Bn	1,894.55 Bn	-	-
3	Akari Therapeutics	1,014.18 Bn	1,014.18 Bn	-	88,604.00
4	BeOne Medicines	471.64 Bn	466.85 Bn	1.35 Bn	-
5	Vertex Pharmaceuticals	121.72 Bn	114.47 Bn	2.59 Bn	-
6	Regeneron Pharmaceuticals	68.28 Bn	59.52 Bn	3.31 Bn	-
7	Belite Bio	61.40 Bn	61.40 Bn	-	-
8	Argenx Se	56.94 Bn	56.94 Bn	1.18 Bn	-
9	Revolution Medicines	37.37 Bn	37.37 Bn	-	19.44 Mn
10	Denali Therapeutics	4.33 Bn	4.33 Bn	-	-

Download Data